Skip to content

Remote Endarterectomy and Endovascular Treatments in Patients With the Femoral Artery Occlusive Disease

Prospective Randomized Clinical Trial of the Remote Endarterectomy and the Femoral Arteries Endovascular Treatments in Patients With the Femoral Artery Occlusive Disease (TASC C, D)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02948166
Enrollment
174
Registered
2016-10-28
Start date
2016-01-31
Completion date
2019-01-31
Last updated
2017-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Steno-occlusive Desease of Femoro-popliteal Arterial Segment

Keywords

remote endarterectomy, Angioplasty with stenting of the superficial femoral artery

Brief summary

Comparison of two methods for revascularization of the superficial femoral artery: remote endarterectomy vs. stenting of the superficial femoral artery cin patients with steno-occlusive lesion of the femoro-popliteal segment of TASC C, D

Detailed description

Reported local percutaneous angioplasty and stenosis of femoral popliteal arteries indicate that the primary technical and clinical success above 95%. The technical success of recanalization of long occlusions femoral arteries less than 80%. Improvement of endovascular equipment designed for the treatment of total occlusions, increases the technical success of recanalization. The materials of the TASC II summarizes the results of several large studies that presented data on the operated segment artery patency at 56-73,7% within 2 years of observation. An alternative method of revascularization own femoral artery is remote endarterectomy. The two-year primary patency at remote endarterectomy is 86% (Moll F.L., Iio G.H. Closed superficial femoral artery endarterectomy: a 2-year follow up. Cardiovasc Surg. 1997; 5: 398-400). Primary assisted patency for 33 months 88% (Rosenthal D, Martin JD, Schubart PJ, Wellons ED. Remote. superficial femoral artery endarterectomy. J Cardiovasc Surg. (Torino) 2004; 45: 185-192). The length of the occlusion is not a limitation to the use of remote endarterectomy. Primary patency at 31 months was 60%.

Interventions

A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent (balloon expandable or self-expanding) of all the extension is mounted.

PROCEDUREOpen surgery

Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of ksenoperikard treated with epoxy compounds. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.

Sponsors

Meshalkin Research Institute of Pathology of Circulation
Lead SponsorNETWORK

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
45 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patients with occlusive lesions of C and D type femoral artery and with chronic lower limb ischemia (II-IV degree by Fontaine, 4-6 degree by Rutherford) * Patients who consented to participate in this study.

Exclusion criteria

* Chronic heart failure of III-IV functional class by NYHA classification. * Decompensated chronic pulmonary heart * Severe hepatic or renal failure (bilirubin\> 35 mmol / l, glomerular filtration rate \<60 mL / min); * Polyvalent drug allergy * Cancer in the terminal stage with a life expectancy less than 6 months; * Acute ischemic * Expressed aortic calcification tolerant to angioplasty * Patients with significant common femoral artery lesion * Patient refusal to participate or continue to participate in the study

Design outcomes

Primary

MeasureTime frame
the change of lumen in target vesselBaseline, 3 days after the operation, 6 month, 12 month, 2, 3 years

Secondary

MeasureTime frame
Number of participants with a successful procedure of revascularization.During the operation.
Number of participants with complications during the operation.During the operation.
Number of participants with limb salvageBaseline, 3 days after the operation, 6 month, 12 month, 2, 3 years

Countries

Russia

Contacts

Primary ContactArtem Rabtsun
a_rabtsun@meshalkin.ru+79137078354

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026